Emerging Therapeutic Strategies for Lysosomal Storage Diseases: Addressing the Challenges of Pharmacotherapy in Rare Genetic Diseases

Lysosomal storage diseases (LSDs) are a group of unusual genetic disorders characterized by defective lysosomal enzymes responsible for substrate accumulation within cells. This disturbance hinders normal cellular functionality and consequent progressive organ damage. Pompe disease, Gaucher disease (GD), and Fabry disease are relatively common examples of LSDs. In Pompe disease, glycogen accumulates in muscle tissues due to the deficiency of acid alpha-glucosidase (GAA), whereas in GD, glucocerebroside accumulates because of the deficiency of glucocerebrosidase, and in Fabry disease, globotriaosyl ceramide accumulates because of the deficiency of alpha-galactosidase A. Different therapeutic strategies are available for these disorders. Enzyme replacement therapy (ERT) provides missing enzymes to limit substrate accumulation while substrate reduction therapy (SRT) decreases substrate levels and alleviates storage stress. Chaperone-mediated therapy (CMT) stabilizes misfolded enzymes to increase lysosomal activity. Gene therapy approaches are under investigation, with some using clustered regularly interspaced short palindromic repeats (CRISPR) technology to induce permanent correction of genetic defects by transferring functional genes. Proteostasis regulators maintain lysosomal function and restore the cellular environment, in turn, restoring enzyme function. Stem cell transplantation offers a potential supply of functional lysosomal enzymes from donor cells. Therefore, the combination of all these emerging approaches provides fresh hope for enhancing therapeutic outcomes against LSDs, overcoming their limitations, and improving the quality of life for LSD patients.